AI / ML Innovations Stock Price, News & Analysis

AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) has announced a marketing services agreement with Frontier Flex Marketing Group to enhance public exposure over 12 months, compensating Frontier $96,000. The company has also issued 1,000,000 stock options to management at an exercise price of $0.20 for five years, pending regulatory approvals. AI/ML Innovations focuses on artificial intelligence and machine learning within digital health, with significant stakes in Health Gauge (100% ownership), Tech2Heal (22% potential ownership), and AI Rx Inc. (70% ownership). The company aims to advance transformative healthcare solutions.

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) has updated its previous announcement regarding a non-brokered private placement. The Company accepted subscriptions for 4,867,748 units at a price of $0.06 per unit, bringing gross proceeds to $292,064.88, lower than the earlier stated 5,086,498 units. AI/ML continues to focus on investments in artificial intelligence (AI) and machine learning (ML), particularly in digital health and wellbeing sectors. The Company holds strategic partnerships, including a 70% ownership in Health Gauge and AI Rx Inc., which aim to enhance healthcare solutions.

AI/ML Innovations Inc. (CSE:AIML; OTCQB:AIMLF) has successfully closed a non-brokered private placement, raising $305,190.04 by accepting subscriptions for 5,086,498 units priced at $0.06 per unit. Each unit comprises one common share and one common share purchase warrant, allowing the purchase of an additional share at $0.10 for two years, with potential acceleration if shares trade at or above $0.20 for 10 consecutive days. A total of 420,000 units were subscribed by an insider. The funds will be used for general working capital, while the securities are subject to a hold period until July 15, 2023.

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) announced that its subsidiary, Health Gauge Inc., completed a successful blood pressure validation study for its wearable device, the Phoenix. This study indicates the device's compliance with regulatory standards for medical devices. The CTO noted the importance of finishing the FDA verification process, which would make Phoenix a Class 2 medical device approved for blood pressure monitoring. The study showcased the effectiveness of Health Gauge's AI technology, revealing minimal mean absolute errors in blood pressure estimations. This milestone supports upcoming FDA and Health Canada submissions, enhancing future business opportunities.

AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) successfully closed its warrant exercise incentive program on January 19, 2023. The program encouraged the exercise of up to 5,648,000 Eligible Warrants at $0.075 per Common Share. A total of 1,845,000 warrants were exercised, generating proceeds of $138,375 for general working capital. Participants received additional Incentive Warrants allowing the purchase of one Common Share at $0.10 until January 19, 2024. The company is focused on the AI and ML sectors, particularly in digital health and wellbeing, through strategic partnerships. For more details, visit AI/ML Innovations.

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) announced a collaboration between its subsidiary, Health Gauge Inc., and TaqTik Health, Inc. to pilot an AI-enhanced remote monitoring solution for obesity patients. The pilot, involving bariatric surgeons in Mexico and Asia, aims to support lifestyle modification and weight loss for patients post-surgery. TaqTik, serving over 35,000 remote obesity patients, will leverage Health Gauge's digital health platform to enhance patient outcomes. The partnership highlights the growing global obesity crisis, with obesity rates tripling since 1975, impacting approximately one billion people by 2030.

AI/ML Innovations Inc. (CSE:AIML; OTCQB:AIMLF) announced the successful closing of its warrant exercise incentive program, encouraging the exercise of 5,648,000 unlisted common share purchase warrants. A total of 2,420,000 Eligible Warrants were exercised, resulting in proceeds of $181,500 for general working capital. Each holder also received an additional warrant, valid until January 9, 2024, for a Common Share at $0.10. The program aims to enhance liquidity and shareholder value as the company expands in the AI and digital health sectors.

AI/ML Innovations Inc. (AIMLF) has announced the launch of its subsidiary Tech2Heal SAS's Alakin ARPC Platform, a comprehensive solution for remote patient care. This 'third-generation' platform enhances patient engagement and streamlines workflows for healthcare providers, addressing limitations found in conventional monitoring systems. Alakin, which complies with HIPAA and supports FHIR standards, offers features such as telemedicine, scheduling management, and a multilingual mobile app. Its flexibility accommodates various healthcare settings, from oncology to primary care, ultimately aiming to improve patient outcomes.